The effects of selected antineoplastic agents on the labeling of erythrocytes with technetium-99m using the UltraTag® RBC kit

Journal of Nuclear Medicine Technology

Volumn 27, Issue 2, 1999, Pages 132-135

  Spicer, Jay A ^a   Hladik III, William B ^b   Mulberry, William E ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Antineoplastics; Labeling interference; Ultratag RBC kit

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PERTECHNETIC ACID TC 99M; VINCRISTINE;

ARTICLE; BLOOD; BLOOD SAMPLING; CHELATION; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN;

ANTINEOPLASTIC AGENTS; DOXORUBICIN; ERYTHROCYTES; HUMANS; ISOTOPE LABELING; REAGENT KITS, DIAGNOSTIC; SODIUM PERTECHNETATE TC 99M;

EID: 0033065985     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fischer J, Wolf R, Leon A. Technetium-99m as a label for erythrocytes. J Nucl Med. 1967; 8:229-232.
2. Bardy A, Fouye H, Gobin R, et al. Technetium-99m labeling by means of stannous pyrophosphate. application to bleomycin and red blood cells. J Nucl Med. 1975; 16:435-437.
3. Smith TD, Steimers JR, Richards P. Chemical effect of Tc-99 on Tc-99m-labeled radiopharmaceuticals [Abstract]. J Nucl Med 1975, 16570-571.
4. 99mTc-red blood cells. J Nucl Med. 1976; 17:133-136.
5. 99mTc-labeled red blood cells. J Nucl Med. 1976; 17:126-132
6. Zimmer AM. In vitro technetium-99m red blood cell labeling using commercial stannous pyrophosphate. Am J Hosp Pharm. 1977;34:264-267
7. Gleue AD, Spicer JA, Preston DF The effect of cyclosporine on technetium-99m red blood cell labeling using the UltraTag® RBC in vitro kit. J Nucl Med Technol. 1995; 23:22-25.
8. Pauwels EKJ, Feitsma RIJ, Blom J. Influence of adriamycin on red blood cell labelling, a pitfall in scintigraphic blood pool imaging. Nucl Med Commun. 1983; 4:290-295
9. Wong GLM. Labelling of red blood cells with Tc-99m for nuclear medicine studies. Can J Hosp Pharm 1991;44:189-194.
10. Lin MS, MacGregor RD Jr, Jano Y, Ionic aluminum (III) in generator eluate as an erythrocyte-agglutinating agent. J Nucl Med. 1971;12:297-299
11. Callahan RJ, Froelich JW, McKusick KA, Strauss HW. Studies of red blood cell (RBC) labeling, rate of binding of Tc-99m to hemoglobin (Hgb) in the intact cellular Hgb solution [Abstract] J Nucl Med 1981,22:P70
12. Seawright SJ, Maton PG, Greenall J, Houle S, McLaughlin PR. Factors affecting in vivo labeling of red blood cells [Abstract]. J Nucl Med Technol 1983;11:95.
13. Mock BH, Wellman HN. Stoichiometnc Tc-99m RBC labeling using stable kit solutions of stannous chloride and EDTA concise communication. J Nucl Med, 1984;25:881-886.
14. Ponto JA, Preslar JS. Poor labeling of technetium-99m RBCs in vivo associated with source of normal saline used for Sn-PYP reconstitution [Letter to Ed]. J Nucl Med Technol. 1990;18:107-108.
15. Kelly MJ, Cowie A, Antonino A, Kalff V. An assessment of factors which influence the effectiveness of the modified in vivo erythrocyte labeling technique [Abstract]. J Nucl Med. 1991;32:1090.
16. Feldkamp M, Spicer J. Problems with technetium-99m-red blood cell labeling [Letter to Ed]. J Nucl Med Technol. 1991;19:50.
17. Kelly MJ, Cowie AR, Antonino A, Barton H, Kalff V. An assessment of factors which influence the effectiveness of the modified in-vivo technetium-99m-erythrocyte labeling technique in clinical use J Nucl Med. 1992; 33 2222-2225
18. Gerson B, Ballinger JR, Gulenchyn KY. Improved modification for in vitro labeling of red blood cells with technetium-99m. J Nucl Med Technol. 1988,16:9-11
19. Lee HB, Wexler JR Scharf SC, Blaufox MD. Pharmacologic alterations in Tc-99m binding by red blood cells: concise communication. J Nucl Med. 1983;24:397-401.
20. Ballinger JR, Gerson B, Gulenchyn KY, Ruddy TD, Davies RA. Technetium-99m red cell labeling in patients treated with doxorubicin. Clin Nucl Med. 1988;13:169-170.
21. Hicks RJ, Eu P, Arkles LB. Efficiency of labelling of red blood cells with technetium-99m after dipyridamole infusion for thallium-201 stress testing. Eur J Nucl Med. 1992,19:1050-1053.
22. Allen ML, McPherson AL, Mertes BJ, Preston DF, Robinson RG. Effects of cyclosponne in lowering red blood cell technetium-99m labeling efficiency. J Nucl Med Technol. 1990;18:191-193.
23. Reisdorff JA, Trevino LD, Velasquez IV D, Jackson M. The effect of cyclosporin concentration on the efficiency of in vitro technetium-99m radiolabeling of red blood cells. J Nucl Med Technol. 1992;20:147-150.
24. Hambye AS, Vandermeiren R, Vervaet A, Vandevivere J. Failure to label red blood cells adequately in daily practice using an in vivo method: methodological and clinical considerations. Eur J Nucl Med. 1995; 22:61-67.
25. 99mTc. Nucl Med Commun. 1982;3:155-161.
26. Dewanjee MK. The chemistry of 99m-Tc-labeled radiopharmaceuticals. Semin Nucl Med. 1990;20:5-27.
27. Leitl GP, Drew HM, Kelly ME, et al. Interference with Tc-99m labeling of red blood cells (RBCs) by RBC antibodies [Abstract]. J Nucl Med. 1980;21:P44.
28. Zimmer AM, Spies SM, Majewski W. Effect of drugs on in vivo RBC labeling: a proposed mechanism of inhibition. Presented at the Second International Symposium on Radiopharmacology: Chicago4. IL; September 1981
29. Tatum JL, Burke TS, Hirsch JI, et al. Pitfall to modified in vivo method of technetium-99m red blood cell labeling. Iodinated contrast media. Clin Nucl Med. 1983;8:585-587.
30. UltraTag® RBC package insert. St. Louis, MO, Mallinckrodt, Inc.: 1991.